Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial

J Neuroophthalmol. 2016 Mar;36(1):6-12. doi: 10.1097/WNO.0000000000000327.

Abstract

Background: To determine the prevalence of visual field (VF) performance failures (PF) and treatment failures (TFs), and identify factors associated with PFs in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Methods: A total of 165 participants from 38 sites with idiopathic intracranial hypertension (IIH) and mild visual loss were randomized to either acetazolamide-plus diet or placebo-plus diet. The IIHTT Visual Field Reading Center evaluated 2950 Swedish Interactive Threshold Algorithm Standard 24-2 VFs from the enrolled participants. A TF was defined when the participant's VF mean deviation (MD) worsened ≥2 to 3 dB from the average baseline MD (range of -2 to -7 dB) with a second retest confirming the visual deterioration. A PF was determined when the participant's: 1) VF results met TF criteria but were not confirmed on retest, 2) deterioration was confirmed on retest but the IIHTT Adjudication Committee concluded a TF was clinically unlikely.

Results: TF was detected in 7/165 (4%) of the participants and PF was detected in 35/165 (21%) of the participants on at least 1 examination. Four of the 35 PFs were adjudicated for TF, however based on clinical review by the adjudication committee and a third retest, they were judged as PFs. Of the 2,950 total IIHTT VF examinations, 2.7% met PF criteria.

Conclusions: PF was confirmed in 21% of subjects and in 2.7% of the total number of VF examinations and was reversible on repeat testing. We recommend retesting when perimetric worsening occurs in otherwise clinically stable or improving IIH patients.

Trial registration: ClinicalTrials.gov NCT01003639.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / therapeutic use*
  • Adolescent
  • Adult
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Combined Modality Therapy
  • Diet, Sodium-Restricted*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Papilledema / physiopathology
  • Pseudotumor Cerebri / diet therapy*
  • Pseudotumor Cerebri / drug therapy*
  • Pseudotumor Cerebri / physiopathology
  • Quality of Life
  • Risk Factors
  • Treatment Failure
  • Vision Disorders / physiopathology*
  • Visual Field Tests
  • Visual Fields / physiology*

Substances

  • Carbonic Anhydrase Inhibitors
  • Acetazolamide

Associated data

  • ClinicalTrials.gov/NCT01003639